Revolution of Alzheimer's Disease Understanding & Trials Through Biomarkers

Biomarkers provide valuable information in the context of clinical trials, both for trial enrichment and for monitoring potential treatment utility. The purpose of this meeting is to apply our understanding of the role biomarkers play in Alzheimer’s disease (AD) to clinical trials. This meeting will provide a forum to discuss fluid and imaging biomarkers for molecular pathologies and to address how altered brain structure and function are increasingly being used in AD research and drug trials. In clinical research, biomarkers provide invaluable in vivo information about different pathological processes during AD development. In drug trials, biomarkers may be used to enrich study populations with subjects at high risk of future cognitive decline, as exemplified by recent trials; however, several major questions remain. For example, it is not clear how to optimally use biomarkers to support disease modification claims and to perform individual risk prediction in pre-clinical stages. Standardizing measurement methodologies to reduce variability over time and between sites remains a challenge. There is also a need for novel biomarkers, both to facilitate measurements of Abeta and tau pathology, and to characterize other aspects of AD and co-pathologies. Strategies for accelerating biomarker discovery and clinical utility in trials in near-term as well as long-term solutions will be explored. Participants will include representatives from industry, academics, and federal/regulatory scientific leadership.

To reserve accommodations in the Association hotel block, a link will be provided immediately following regisration.